Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7749363 | 0.88 | CYP2A6 (0.52) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL12314999 | 0.86 | CYP2A6 (0.54) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL10245976 | 0.84 | MTNR1A (0.50) | CA2MAPT | |
| SCHEMBL7744805 | 0.84 | MTNR1A (0.36) | CYP2A6KEAP1NFE2L2CA2 | |
| SCHEMBL14706590 | 0.84 | CYP2A6 (0.51) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL12314972 | 0.83 | CYP2A6 (0.59) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL8289099 | 0.82 | KEAP1 (0.48) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL3141736 | 0.81 | KEAP1 (0.58) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL12314995 | 0.80 | CYP2A6 (0.55) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL8290998 | 0.78 | KEAP1 (0.44) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101827599-B | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA NV | 2013-08-28 | — | — | CN | disclosed |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | ANZALONE LUIGI (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | ANZALONE LUIGI (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | ANZALONE LUIGI (US) | 2012-10-11 | — | — | US | disclosed |
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | disclosed |
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | disclosed |
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | disclosed |
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | disclosed |
| CN-101827599-A | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA NV | 2010-09-08 | — | — | CN | disclosed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CYP2A6 1090/4885KEAP1 466/4885NFE2L2 3735/4885 |
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CYP2A6 1090/4885KEAP1 466/4885NFE2L2 3735/4885 |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | CYP2A6 1122/4885KEAP1 2465/4885NFE2L2 4837/4885 |
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | CMA1, CPA3, CPA1 | CYP2A6 1801/4885KEAP1 1462/4885NFE2L2 4238/4885 |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | CMA1, PPA1, CPN1 | CYP2A6 1122/4885KEAP1 2465/4885NFE2L2 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.